Drug Channels delivers timely analysis and provocative opinions from Adam J. Fein, Ph.D., the country's foremost expert on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 65,000 subscribers and followers. Learn more...
Today’s guest post comes from Logan Melchione, Senior Director of Account Management at Paysign.
Logan discusses the financial impacts of copay accumulators on manufacturers and patients. She describes how to reduce the strain on manufacturers' programs while also increasing patient access. Click here to learn about the Paysign Solution.
Email affordability@paysign.com to set up a meeting with Paysign at Asembia’s Specialty Pharmacy Summit, April 30-May 4.
Spring is here in sunny downtown Philadelphia, worldwide headquarters of Drug Channels. The vernal equinox has brought us an unexpected bounty of noteworthy news:
Thoughts on the recent insulin price cuts by Lilly, Novo, and Sanofi
AbbVie gets tougher on alternative funding programs
Optum quietly adds a new drug channel role
A novel partnership emerges to modernize the 340B program
Plus, a celebration of pharmacists’ activities during the COVID-19 pandemic.
Exclusive Offer for Drug Channels Readers: Register Now to SAVE 10%* using promo code 23DC10
Informa Connect’s 19th Annual Commercial Contracts & Chargebacks Congress, taking place May 16-17 in Washington, DC, offers crucial updates on policy changes and contracting best practices to increase efficiency, reduce revenue leakage, and streamline chargeback excellence. This annual event has become a must-attend for pricing and contracting professionals in the life sciences industry with seasoned leaders and forward-thinking strategies on display. Join industry stakeholders, including manufacturers, wholesalers, GPOs and more, for a robust two-day event offering extended content and actionable strategies in key interest areas in the ever-evolving contracting landscape.
Featured Faculty Driving the Conversation:
Rosalind Davis, Government Pricing & Contracts Director, Vifor Pharma, Inc.
Stephani Kupski, Director, U.S. Pricing & Government Reporting, CSL Behring
Mallory O’Connor, Public Policy Executive Director, Mallinckrodt
Cad Snyder, Director, Global Finance Shared Services, Cardinal Health
Beth Stevens, Associate Director, Contracts and Pricing, Tolmar Inc.
Roxana Santiago, Director Controlling Revenue Accounting, Fresenius Kabi USA LLC
Jennifer Plemmons Crosswell, Director, Contracts & Pricing, Accounting, Azurity Pharmaceuticals
Hight Impact Topics Transforming the Market Include:
Commercial Contract Model Landscape
Assessing the Impact of IRA on Product Calculations
340B Drug Discount Program — Ongoing Monitoring of 340B Program Risks & Best Practices
Multi-Stakeholder Panel — Membership and Class of Trade
Updated Review and Interpretation of the Inflation Reduction Act
GTN Forecasting Across Different Channels
PLUS! — Customize Your Learning by Choosing Between Two Thought-Provoking Tracks:
Contracts and Chargebacks Excellence
Analytical and Technology Innovation
and more!
NEW THIS YEAR! The 2023 Summit is Part of Life Sciences Pricing & Contracting USA
Uniting three industry leading events — Medicaid & Government Pricing Congress, Drug Pricing Transparency Congress and Life Sciences Commercial Contracts & Chargebacks — Life Sciences Pricing & Contracting USA is the industry’s go-to resource for gaining critical insight on regulatory requirements, policy initiatives and best practices to enhance pricing and contracting models. Attend your preferred event and prepare for critical content tailored to your focus area, plus benefit from a more diverse speaking faculty and greater networking opportunities to expand your network and establish powerful partnerships.
ENHANCE YOUR EXPERIENCE!
Attendees of Commercial Contracts & Chargebacks 2023 have the option to add a third day of content to their schedule and join the Medicaid & Government Pricing Congress attendees for their final day. Benefit from a fireside chat, in-depth sessions and learning streams, plus additional networking opportunities!
Drug Channels readers are eligible for an exclusive savings of 10% off* the standard rate by using promo code 23DC10, so download the complete conference agenda and reserve your seat today!
*Expires 5/16/2023; applies to current rate only and may not be combined or applied to existing registrations; other restrictions may apply
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Today’s guest post comes from Rhiannon Naslund, Chief Marketing Officer at Kalderos.
Rhiannon discusses the growing collaboration between manufacturers and covered entities regarding 340B discount claims. She goes on to describe the Kalderos Discount Hub solution that reviews claims that have a high likelihood of being a duplicate discount.
12 chapters, 480+ pages, 241 charts/exhibits/data tables, 966 endnotes: There is nothing else available that comes close to this encyclopedic resource.
The chart below illustrates the depth and breadth of the 2023 edition. The numbers indicate the report chapter that corresponds to, explains, and analyzes each channel flow.
[Click to Enlarge]
If you would like to pay by corporate purchase order or check, please email Tamra Feldman. If you preordered the report, you should have already received an email with download instructions last week. Please contact us if you did not receive the email.
Join the life science industry on May 16-18, 2023 in Washington, DC at the Medicaid & Government Pricing Congress to conquer complex Medicaid regulatory guidelines and evolve strategies to contract, report and comply with federal and state healthcare programs.
View the agenda for Medicaid & GP 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/medicaid-government-pricing for further details and to register. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to April 7, 2023.*
When you join Informa Connect in Washington, DC, you'll hear from leading GP experts on the latest MDRP trends and strategies that impact you and your business. Some of the companies leading the dialogue include Ascendis Pharma, AstraZenca, Bayer, Blueprint Medicines, Bristol Myers Squibb, CSL Behring, Department of Health & Human Services, Endo, Genentech, Gilead, Mallinckrodt, Neurocrine Biosciences, Novartis, Pfizer, PhRMA, Sanofi, Takeda, Teva, UCB, United Therapeutics, Viatris and more.
Here are just a few of the sessions you'll attend:
Everything Inflation Reduction Act – Both interpretation and implementation guidance
Your Medicaid wish list – 30+ years into the program, what would your recommendations to CMS be?
The latest and greatest 340B litigation and operational updates
Refresh of the inclusion of territories, and hear from Puerto Rico Medicaid on their processes
Panel on market access and pricing strategy considerations for early R&D
Join a senior-level work group on policy reform for Medicaid and government pricing programs
Discuss the intersection of line extensions and AMP cap in-depth
Back by popular demand – Fundamentals of GP, the fireside chat with external counsel, and the state-by-state review of SPTR
Topics on class of trade, strategies for product launch, moving your data to the cloud, intro to blockchain for GP professionals, discussion on bots and automation and much more!
Informa Connect is also thrilled that this year's Congress is part of Pricing & Contracting USA! You'll have the benefit of networking with like-minded executives from across the life science industry as we bring together attendees from three industry leading events (the Medicaid & Government Pricing Congress, the Drug Pricing Transparency Congress and the Commercial Contracts & Chargebacks Summit) in the pricing and contracting arena.
View the agenda for Medicaid & GP 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/medicaid-government-pricing for further details and to register. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to April 7, 2023.*
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx.
Stacey discusses digital hubs and the affordability advantages they offer both patients on specialty therapies and their health care providers. To learn more, click here to schedule a meeting with AssistRx at Asembia’s Specialty Pharmacy Summit on April 30 to May 4, 2023.
The exhibit below—one of 241 in our new report—provides a first look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for calendar year 2022. U.S. prescription dispensing revenues reached a record $548 billion in 2022.
Not to put too fine a point on it—but they might be giants. The largest 15 pharmacies accounted for more than 75% of total dispensing revenues from retail, mail, long-term care, and specialty pharmacies. The top 15's share dipped slightly compared with their 2021 share, due primarily to the significant revenue losses for Walgreens Boots Alliance’s AllianceRx Walgreens Pharmacy.
This page describes the event and explains how to purchase a registration. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.
The rapid expansion of patient-paid prescriptions—via cash-pay pharmacies and discount card vendors—is transforming the prescription market. Join Dr. Fein as he helps you and your team deepen their understanding of this important issue and its crucial implications. He will draw from exclusive information found in DCI's new 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.
During the event, Dr. Fein will cover a wide range of topics, including:
What’s driving the boom in patient-paid prescriptions
The warped economics of the generic prescription channel
Cash-pay prescriptions vs. discount cards
Why Usual & Customary (U&C) prices matter
The latest market data on the discount card market and its key participants
The complex economics of discount cards
How PBMs profit from—and are challenged by—patient-paid prescriptions
Pharmacy strategies and reactions
Why and how plans are placing discount cards within pharmacy benefits
Commentary on GoodRx, Mark Cuban Cost-Plus Drug Company, and more
Outlook for disruption of the pharmacy benefit market
Controversies and unresolved questions
And more!
PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions.
As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data.
Read on for full details on pricing and registration. PRICING OPTIONS
You can register for this unique educational opportunity for only $380 per viewing device. Within 24 hours of your purchase, you will receive an email from Zoom with a unique link to access the webinar replay video.
We are offering substantial discounts for multiple registrations from the same organization. We know that many of you may still be working from home, so rates for multiple registrations are as low as $265 per device—a 30% savings. An unlimited number of people may watch at one location if they can watch from a single device.
Click here to order. All discounts will be automatically computed based on the number of registrations you enter in your cart. (You can reset the cart by entering 0 in the quantity field.)
Watch and listen via any device with a web browser (computer, iPad, iPhone/Android, etc.) There is no access via telephone.
We use Zoom technology for this webinar. Every registrant will receive an email from Zoom with a link to watch the event. This link is unique to the registrant and can only be accessed once. We recommend that every registrant download the Zoom client software/app.
Prior to the event, every registrant will receive an email from Zoom with a link to access the event and add it to their calendar. Every registrant will also receive reminder emails from Zoom one week, one day, and one hour before the event.
This event is part of The Drug Channels 2023 Video Webinar Series. If you have already purchased the full series, you should have received an email from no-reply@zoom.us with your unique link to access the event.
Organizations that purchased corporate access for The Drug Channels 2023 Video Webinar Series will receive a custom, branded signup link so employees can easily register. We will automatically refund payments from anyone at a company with corporate access who purchases a single registration using their corporate email account.
Join Informa Connect on May 16-17, 2023 in Washington, DC at the Drug Pricing Transparency Congress to stay on the pulse of federal and state reporting requirements, policy initiatives and strategic best practices for compliance. Experts from across the industry will discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Plus, assess how companies are internally planning for these changes.
View the agenda for Drug Pricing Transparency 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/drug-pricing-transparency for further details and to register. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*
Here's just a little sneak peek at what's to come:
You'll hear perspectives from the who's who in drug pricing and transparency, including companies such as Actelion, Ascendis Pharma, BIO, Chiesi, ClassOne Insight, Endo, Gilead Sciences, Hyman, Phelps & McNamara, iContracts, King & Spalding, Latham & Watkins, Mallinckrodt, Maryland Prescription Drug Affordability Board, Model N, Neurocrine Biosciences, Novartis, Novo Nordisk, PhRMA, Porzio Life Sciences, Riparian, Sanofi, Teva, U.S. Attorney's Office for the Districts of MA and NJ, and Viatris
You'll take a deep dive into the hottest topics keeping you up at night, including
Drug Pricing Transparency Pressures
DOJ Drug Pricing Transparency Priorities
Legal Updates on Authorized Generics and the U.S. Drug Pricing of Brand Name Drugs
Resource Allocation for Your Medicaid, Market Access and GP Teams
Updated Review Including CMS Guidance of the Inflation Reduction Act
Implication of Stacked and Value Based Contract Product Agreements on Medicaid Pricing
And much more!
Informa Connect is also thrilled that this year's Congress is part of Pricing & Contracting USA! You'll have the benefit of networking with like-minded executives from across the life science industry as we bring together attendees from three industry leading events (the Medicaid & Government Pricing Congress, the Drug Pricing Transparency Congress and the Commercial Contracts & Chargebacks Summit) in the pricing and contracting arena.
View the agenda for Drug Pricing Transparency 2023 to see the complete picture – the program, speakers, and more, and visit www.informaconnect.com/drug-pricing-transparency for further details and to register. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
The era of artificial-intelligence chatbots has arrived! I am pleased to report that this month’s Drug Channels news roundup was most definitely not written by ChatGPT. No promises about future articles. (See our forecast to the right.)
In this issue:
Mark Cuban explains his anti-PBM strategy
What physicians think about Humira biosimilars
States go after PBMs
HHS is confused about 340B transparency
Plus, The Onion tests your knowledge of United Healthcare’s policies.
Today’s guest post comes from Matt Hall, President of Patient Solutions at CareMetx.
Matt shares three key findings from CareMetx’s exclusive new survey on patient support services for specialty pharmaceuticals. To learn more, download CareMetx’s free 2022 Report - Patient Services Trends.
Is the gold rush in copay accumulators and maximizers slowing down?
Our latest update finds that for 2022, about 40% of commercial lives have adopted these benefit designs. Accumulator adoption has plateaued, while maximizer use has overtaken accumulators. Patients who take a single-source, brand-name specialty drug for autoimmune conditions, multiple sclerosis, and oncology increasingly face these benefit designs. Check out the plan and patient data below.
Patients are caught in the middle of a complex battle among insurers, PBMs, and drugmakers. They are rightfully unhappy that their plans are grabbing the copay support funds. That’s why legislation, lawsuits, and patient advocacy are growing. Manufacturers are also pushing back on plans’ copay games.
These reactions will slow the financial windfall for plans and PBMs—and raise the risk that plans will push the ethical boundaries even farther.
On March 14, 2023, Drug Channels Institute will release The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This report—our fourteenth edition—remains the most comprehensive, fact-based tool for understanding the entire U.S. drug pricing, reimbursement, and dispensing system.
12 chapters, 480+ pages, 241 exhibits, 900+ endnotes: There is nothing else available that comes close to this valuable resource.
We are providing you with the opportunity to preorder this thoroughly updated, revised, and expanded 2023 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive a download link before March 14.
Special preorder and launch pricing discounts will be valid through April 3, 2023.
The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.
As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs. Throughout the report, we have added new industry data, deepened our coverage of many topics, and added more trending information. Material that addresses COVID-19 and its impact on the pharmacy and PBM industries has been integrated into our analyses throughout the report.
This 2023 edition includes substantial new material. A new Section 12.5. addresses the Inflation Reduction Act of 2022. In Subsection 12.5.1., we summarize the key provisions of the law that relate to the topics in this report. In Subsection 12.5.2., we highlight potential implications of the IRA for the drug channel.
The chart below illustrates the depth and breadth of the 2023 edition. The numbers indicate the report chapter that corresponds to, explains, and analyzes each channel flow.
[Click to Enlarge]
Thank you for your interest in our work. If you have any questions before purchasing a license to the report, please email me. Enjoy!
This Valentine's Day, what could be more romantic than a deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and exclusive specialty pharmacy networks.
Below, we rely on a unique database to provide you with some never-before-published benchmarking data on manufacturer-defined networks for 290 specialty drugs.
As you’ll see, a typical network contains only five specialty pharmacies. However, this average disguises substantial variability in network size. More than one in four specialty products have an exclusive network, while some have as many as 25 participants.
Manufacturers almost always say “be mine” to pharmacy benefit manager (PBM) affiliated partners, but they also swipe right with unaffiliated specialty pharmacies. Alas, PBM and plan strategies can still make smaller pharmacies feel lonesome.
As you've surely heard, Amgen has just launched Amjevita, the first non-interchangeable biosimilar of Humira. Our crazy drug channel led Amgen to launch both a high-list/high-rebate and a low-list/low-rebate version of the drug. Its strategy echoes the pricing of the first interchangeable insulin biosimilars—as I predicted in 2021.
Unfortunately, we should expect most PBMs and plan sponsors to embrace the high-list/high-rebate version. The plans that adopt the higher-priced biosimilar will get bigger rebates, while patients with coinsurance and deductibles end up paying more out-of-pocket.
As Mark Twain said: “History doesn’t repeat itself—but it often rhymes.” So, below, I revisit the surprising market dynamics for the interchangeable insulin biosimilars and highlight Amgen’s experience lowering the list price of its PCSK9i product. The story is more complex than you might expect, so perhaps there is hope that low-list-price versions will connect.
Exclusive Offer – Be sure to use your exclusive promo 23AUSA10 to save 10% off* of your registration
We would like to introduce to you Access USA, industry’s resource for accelerating access, partnerships and collaboration to deliver superior patient outcomes.
What is Access USA? Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and Rare Disease Innovation & Partnership Summit, three industry-leading access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships.
Who will be there? Join leading bio/pharma manufacturers, impactful non-profit organizations, top-tier hospitals, foremost health clinics, top-notch PBMs, inspiring advocates, prominent specialty pharmacies, highly regarded academics, leading solution providers and more as they unite to tackle the barriers of patient access and take the necessary steps toward ensuring no patient worry about access to care.
What does that mean for you? In one week, meet with hundreds of key stakeholders across the access landscape and benchmark with, learn from and network with leaders paving the way in patient access. Just choose your preferred event and prepare to walk away inspired and armed with the knowledge necessary to drive patient access forward.
Here are just a few can’t miss content highlights from PAP – Patient Assistance & Access Programs. View the full agenda here.
State of the Industry: The Changing Landscape of Healthcare Coverage and Access
PhRMA Keynote Address
Equity Spotlight: Understanding the Importance of Equitable Healthcare, Education and Partnerships
Manufacturer PAP Spotlight: Gain Insight on Best Practices and Industry Standards
Customizable Track Programming by PAP Legal & Policy, Patient Adherence Strategies or Technology, Innovation & Automation
Workshop Breakout – Advocacy Insights to Enhance Patient Care or Partnership and Development to Optimize Patient Access
Here are just a few can’t miss content highlights from Rare Disease Innovation & Partnership Summit. View the full agenda here.
Navigate FDA Updates on Rare Disease Product Development
Establish and Navigate the Relationship between Industry and Advocacy
Advancing Rare Disease Research with Patient Centrality and Precompetitive Approaches – A Screen4Care Case Study
Rare Disease Awareness – Delivering Authentic Lived Experiences in a Challenging Regulatory Landscape
The 4Ps of Precision Medicine – Patients, Providers, Partners and Pharma
Breakout into Tracks – Access and Reimbursement Strategies, Investing and Partnering, and Drug Development and Clinical Innovation
Here are just a few can’t miss content highlights from Hub and Specialty Pharmacy Models East. View the full agenda here.
Policy Address – State of the 2023 Industry and Payer Landscape for Industry Trend Updates
Hubs Stakeholder Showcase – Opportunities and Challenges in Accelerating Patient Access with Manufacturer, SPP and Consultant Perspectives
Copay Landscape – Changes in the Accumulator/Maximizer Landscape and How to Prepare
Enforcement Panel – Explore Evolving Regulatory Reform in the Patient Support Services and Hub Models Space
Customizable Tracked Programming by Patient Support & Engagement or Digital & Technological Innovation
Exclusive Offer – Choose your preferred event and register today – Be sure to use your exclusive promo 23AUSA10 to save 10% off* of your registration
Informa Connect will see you there!
*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Here at our worldwide headquarters in Philadelphia, Eagles Super Bowl fever has landed. The police are already getting extra Crisco for the light poles. (Yes, really.)
Before you start training to gorge at your game day party, tackle this month’s selection of notable news stories, intercepted for you from the Drug Channels gridiron:
Offsides: My $0.02 on the latest moves by Amazon and OptumRx
Trick play: OptumRx attacks alternative funding programs
Offensive line: Shocking Wall Street Journal expose of 340B abuses
Touchdown! Accumulators and maximizers go mainstream
Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT.
Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.
Now that 2023 is underway, let’s review employer-sponsored coverage for prescription drugs and speculate on what’s ahead.
Below I examine the latest data on pharmacy benefits: cost sharing tier structures, copayment vs. coinsurance, and out-of-pocket obligations. As you will see, pharmacy benefit designs again increased the use of coinsurance for specialty and fourth-tier drugs.
These designs significantly raise patients’ out-of-pocket obligations—and contribute to the controversy over copay accumulator adjustment and copay maximizers. In 2023, employers’ savings and PBMs’ profits from these programs will decline—which will trigger a coming crackdown on specialty drug benefits. Beneficiary beware!
P.S. As usual, you will also enjoy some terrible Drug Channels tiers/tears puns.
Exclusive Offer – Be sure to use your exclusive promocode 23DCPAP10 to save 10% off* your registration.
The last thing a patient should worry about is access to care. With growing demand for patient assistance, accelerating prescription access and affordability is as crucial as ever. PAP – Patient Assistance & Access Programs is back March 20-22 and bringing together key stakeholders to collaborate and strategize on methods to meet that growing demand and navigate the access and reimbursement barriers faced daily.
Join your peers, leading experts and top solution providers for unparalleled networking opportunities and fresh perspectives on how to further access to care, understand current changes in legislation and policy and optimize PAP programs for better patient outcomes. Industry standards are evolving. Secure your spot now to ensure you and your organization are not left behind.
Do not miss this opportunity to unite with pharma, foundations, health clinics and more and benchmark on industry standards and stay on top of evolving trends to propel program performance. Can’t miss content highlights include:
State of the Industry: The Changing Landscape of Healthcare Coverage and Access
PhRMA Keynote Address
Equity Spotlight: Understanding the Importance of Equitable Healthcare, Education and Partnerships
Patient Perspective
Manufacturer PAP Spotlight: Gain Insight on Best Practices and Industry Standards
Three Customizable Tracks
PAP Legal & Policy
Patient Adherence Strategies
Technology, Innovation & Automation
Two Workshops
Advocacy Insights to Enhance Patient Care
Partnership and Development to Optimize Patient Access
And more!
PLUS, EXTENDED NETWORKING IN 2023!
PAP 2023 will take place as part of Access USA, the access event bringing together three industry-leading conferences under one roof. Benefit from robust networking opportunities with all Access USA participants (that is an expected 600+ access professionals!) and expand your network and establish powerful partnerships.
Exclusive Offer – View the agenda and register today – Be sure to use your exclusive promocode 23DCPAP10 to save 10% off* your registration..
Informa Connect will see you there!
*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein(paula@drugchannels.net).
Today’s blog post comes from Andrew Duncan, Vice President of Business Operations and Analytics at PHIL.
Andrew discusses how manufacturers can use data-driven strategy to understand utilization, increase patient access and adherence, and optimize gross-to-net.
Consolidation has brought together large, economically significant insurer/PBM/specialty pharmacy/provider organizations within U.S. drug channels. At least half of all U.S. healthcare spending flows through these seven familiar entities: Blue Cross Blue Shield, Centene, Cigna, CVS Health, Elevance Health, Humana, and United Health Group.
In the brief video clip below, I review these businesses and offer some thoughts on their positioning for 2023. As you’ll see, the vertical strategy shakeout is underway.
.jpeg)
.jpeg)
